1. Home /
  2. Biotechnology


Cassava Sciences Is Overbought But Still Points Higher

Here's where traders could go long SAVA.

Cybin Raises Cash, but Is There a Catch?

The psychedelic therapeutics biotech pulled in an additional $30 million in Canadian dollars; let's figure out why and what it means -- and why it's kinda weird.

Taking Another Look at 2 Stocks I Like While Waiting for Breadth to Broaden

Recent news about Travelzoo and Albireo Pharma offer reasons to think those shares could be heading higher.

Jim Cramer: There's a Way for the Pandemic to End But It's a Terrible Way

We are a nation divided between those who are rabid to take the vaccine and those who are not.

I Predict a Good Trade in Seer

Let's look at how to play this biotech that provides tools for better understanding the proteome.

I'm Happily Keeping My Covered Call Options Rolling, Rolling, Rolling

The simple strategy may not make for home runs but is producing a number of singles and doubles in a dicey market.

Veru Is Pointed Lower Now

Charts suggest there could be further downside risk.

No Rush for the Exits, but Not Much Conviction, Either

It's tough to have much confidence in this market, but a few things are working.

2 Small Stocks to Watch as Conditions Ripen for Biotech Merger Deals

Ardelyx Inc. and Rigel Pharmaceuticals look good as stand-alone companies but also could attract suitors.

Our Technical Strategy for Speculative Anavex Life Sciences

Let's check the charts and indicators.